EuroAPI gains on market debut after spin-off from Sanofi

Sanofi shareholders will receive one EuroAPI share for 23 shares held in the parent company.;

Published On 2022-05-08 03:30 GMT | Update On 2022-05-08 03:31 GMT

New Delhi: Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.

EuroAPI traded at around 12.25 euros at 0915 GMT, valuing the contract manufacturer's equity at 1.15 billion euros ($1.21 billion) and up 2% from its reference price of 12 euros.

The stock premiered in choppy markets, with world stocks falling towards their lowest in over a year as investors anticipated more U.S. interest rate rises and worried about the hit to growth from China's zero-COVID policy.

The STOXX Europe 600 Health Care index was down 1.7%, while France's blue chip index was off 1.5%.

"What a remarkable day it is," said EuroAPI Chief Executive Karl Rotthier after ringing the opening bell in Paris.

"It's my birthday, that's another good start," added Rotthier, who joined in early 2020 from Dutch pharma ingredients maker Centrient Holding.

Sanofi shareholders will receive one EuroAPI share for 23 shares held in the parent company.

Sanofi shares were down 0.2%, when adjusting for EuroAPI's separation and the payout of a 4.07 billion ordinary dividend.

Sanofi, which will keep a 30% stake, distributed 58% of EuroAPI's equity capital to Sanofi shareholders as a dividend in kind. The French state will acquire 12% in the new company, based on the average market price over the next 30 days.

The group joins rivals including Siegfried and Lonza as stand-alone ingredients and services suppliers to the drugs industry.

As an independent group, EuroAPI has said it will push to win over more of Sanofi's rivals as customers and expand in high-margin drug development services.

Pharma groups that, unlike Sanofi, continue to produce drug ingredients for other drugmakers include Pfizer, Teva and family-owned Boehringer Ingelheim.

EuroAPI's flotation comes as the coronavirus pandemic and Russia's attack on Ukraine have heightened concerns in the European Union over the region's dependency on critical pharma ingredient imports.

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

EuroAPI gains on market debut after spin-off from Sanofi

Sanofi shareholders will receive one EuroAPI share for 23 shares held in the parent company.;

Similar News

Lupin bags USFDA approval for Multiple myeloma treatment

Biocon Biologics wins USFDA nod for Bosaya and Aukelso, Denosumab Biosimilars

Cocrystals of Approved APIs to Be Treated as New Drugs, Clarifies CDSCO

India ranks among top global contributors in adverse event reporting: DCGI

Marketers Linked to Defaulting Pharma Units Under DCGI Lens

Intas Pharma Secures CDSCO Panel Approval for Post-Marketing Study of Tacrolimus Enema

Health Authorities Crack Down on OTC Sale of Antibiotics, NRx Drugs in Visakhapatnam

Merck gets USFDA Breakthrough Therapy Designation for Raludotatug deruxtecan for Platinum-Resistant Ovarian Cancer